TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30452533

Group type: EXPERIMENTAL
Intervention: High-to-moderate-low systolic BP trajectory
Number of subjects: 4036

Group type: EXPERIMENTAL
Intervention: Moderate-high systolic BP trajectory
Number of subjects: 4036

Group type: EXPERIMENTAL
Intervention: Moderate-low systolic BP trajectory
Number of subjects: 4036

Group type: EXPERIMENTAL
Intervention: Low systolic BP trajectory
Number of subjects: 4036
Study: 27663098

Group type: EXPERIMENTAL
Intervention: Proenkephalin (pro-ENK)
Number of subjects: 1684
Study: 25798575

Group type: EXPERIMENTAL
Intervention: Discontinuation of statin therapy
Number of subjects: 381

Group type: COMPARATOR
Intervention: Continuation of statin therapy
Number of subjects: 381
Study: 23913868

Group type: EXPERIMENTAL
Intervention: Small airway deposition of dornase alfa
Number of subjects: 38

Group type: COMPARATOR
Intervention: Large airway deposition of dornase alfa
Number of subjects: 38
Study: 22506302

Group type: EXPERIMENTAL
Intervention: Rockumentary music therapy intervention
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Recreational music therapy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Rockumentary music therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Verbal therapy
Number of subjects: 141
Study: 19150064

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day (A80)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg + Ezetimibe 10 mg per day (A10E10)
Number of subjects: 58
Study: 17803058

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 24
Study: 15197202

Group type: EXPERIMENTAL
Intervention: Preoperative external-beam radiotherapy with boost (85 Gy in three fractions) using endocavitary contact x-ray
Number of subjects: 88

Group type: COMPARATOR
Intervention: Preoperative external-beam radiotherapy (39 Gy in 13 fractions over 17 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 11826764

Group type: EXPERIMENTAL
Intervention: alpha‐follitropin
Number of subjects: 20

Group type: COMPARATOR
Intervention: beta‐follitropin
Number of subjects: 20

Group type: COMPARATOR
Intervention: urofollitropin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups (alpha‐follitropin, beta‐follitropin, urofollitropin)
Number of subjects: 20
Study: 9512151

Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 69
Study: 7869212

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.65 ± 0.07 IU.kg‐1.wk‐1) and gonadotropin-releasing hormone analogs (66 ± 9 micrograms.kg‐1 every 28 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Growth hormone administered alone after interruption of gonadotropin-releasing hormone analogs
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (seven untreated girls)
Number of subjects: 7
Study: 2531718

Group type: EXPERIMENTAL
Intervention: Alpha-hANP administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo pre-treatment
Number of subjects: 12
Study: 3086

Group type: EXPERIMENTAL
Intervention: Lorazepam (Temesta)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Complete placebo (orally and by vaccine)
Number of subjects: 55
Study: 31970393

Group type: EXPERIMENTAL
Intervention: Universal glove and gown use
Number of subjects: 20246
Study: 31628558

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser therapy (1500 J total energy, thrice/week for four weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser therapy plus physical exercise program
Number of subjects: 40
Study: 30940164

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA) delivered during secondary school physical education (PE) - an additional 10 min of VPA per PE lesson for one academic year.
Number of subjects: 0

Group type: COMPARATOR
Intervention: PE as usual (control condition).
Number of subjects: 0
Study: 28472383

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1669
Study: 26306736

Group type: EXPERIMENTAL
Intervention: Arm bracing posture
Number of subjects: 16
Study: 22821223

Group type: EXPERIMENTAL
Intervention: Oral appliance with mandibular advancement (active group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral appliance without advancement (control group)
Number of subjects: 72
Study: 22019126

Group type: EXPERIMENTAL
Intervention: Hysteroscopy guided endometrial biopsy
Number of subjects: 678

Group type: COMPARATOR
Intervention: Control group (patients without endometritis)
Number of subjects: 678
Study: 17868383

Group type: EXPERIMENTAL
Intervention: 125 ng/m(2) body surface area of synthetic ACTH
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 250 ng/m(2) body surface area of synthetic ACTH
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 500 ng/m(2) body surface area of synthetic ACTH
Number of subjects: 6
Study: 16949482

Group type: COMPARATOR
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 900 mg clopidogrel loading dose
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All clopidogrel doses
Number of subjects: 103
Study: 12940611

Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg following dialysis (Phase I)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vancomycin 15 mg/kg during the last hour of hemodialysis (Phase II)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vancomycin 30 mg/kg during the last 2 hours of hemodialysis (Phase III)
Number of subjects: 9
Study: 10852529

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (875/125 mg) administered orally 2 to 4 hours before surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Amoxicillin alone (implied as a comparison)
Number of subjects: 23
Study: 9488196

Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc), a third generation calcium channel blocker (CCB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0
Study: 8450247

Group type: EXPERIMENTAL
Intervention: 3 MIU of systemic recombinant interferon-alpha 2a given three times weekly for 4 weeks after CO2 laser ablation
Number of subjects: 130
Study: 3698458

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg for 15 days followed by 0.3 mg/kg for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam (0.8 mg/kg for 15 days followed by 1.2 mg/kg for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam and Oxazepam (both)
Number of subjects: 0
Study: 30632321

Group type: EXPERIMENTAL
Intervention: Social attention training game
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control game
Number of subjects: 66
Study: 29481695

Group type: EXPERIMENTAL
Intervention: Middle ear implants (MEIs)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional hearing aids (HAs)
Number of subjects: 91
Study: 26613955

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (Arctic Root) for 14 days pretreatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (without Rhodiola rosea)
Number of subjects: 13
Study: 24617812

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum OLB6378 (B. bifidum)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 22273743

Group type: EXPERIMENTAL
Intervention: Two-step self-etch adhesive (Silorane System Adhesive, 3M ESPE: SSA) with low-shrinking composite (Filtek Silorane, 3M ESPE: FS)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (N'Durance, Septodont: N'D)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (Kalore, GC: Ka)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (G-Bond, GC) with conventional composite (Z100, 3M ESPE)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Layering method with all composites
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Two-step self-etch adhesive (Silorane System Adhesive, 3M ESPE: SSA) with conventional composite (Z100, 3M ESPE)
Number of subjects: 5
Study: 20630169

Group type: EXPERIMENTAL
Intervention: Nutrition Labels
Number of subjects: 47

Group type: COMPARATOR
Intervention: No Labels
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nutrition Labeling Education
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Organic Food Movement
Number of subjects: 47
Study: 16914369

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 36
Study: 16301878

Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (moderate dose, 50% above seizure threshold; n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bitemporal ECT (low dose, just above seizure threshold; n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT (high dose, 400% above seizure threshold; n = 15)
Number of subjects: 45
Study: 12173784

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg (loading dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 32
Study: 9528867

Group type: EXPERIMENTAL
Intervention: Spiral computed tomographic pulmonary angiography (SCTA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lung ventilation‐perfusion scintigraphy (VQS)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SCTA
Number of subjects: 78

Group type: COMPARATOR
Intervention: VQS
Number of subjects: 78
Study: 8846800

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2496993

Group type: EXPERIMENTAL
Intervention: Piperacillin and placebo
Number of subjects: 396

Group type: COMPARATOR
Intervention: Ampicillin and amikacin
Number of subjects: 396
Study: 29680845

Group type: EXPERIMENTAL
Intervention: arthrocentesis plus methylprednisolone acetate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: arthrocentesis plus sodium hyaluronate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: arthrocentesis plus tenoxicam
Number of subjects: 44

Group type: COMPARATOR
Intervention: arthrocentesis alone
Number of subjects: 44
Study: 27473164

Group type: EXPERIMENTAL
Intervention: Person-centered progressive resistance exercise
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 130
Study: 25633200

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied once every other day
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.5% timolol maleate eye drops applied thrice daily
Number of subjects: 54
Study: 24237006

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 950

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 950
Study: 20484090

Group type: EXPERIMENTAL
Intervention: Decision aid alone
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Decision aid plus personalized risk assessment
Number of subjects: 665

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 665
Study: 18637604

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg.kg(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg
Number of subjects: 20
Study: 16767526

Group type: EXPERIMENTAL
Intervention: Teriparatide (20-mug subcutaneous, once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiresorptive treatment (control group)
Number of subjects: 60
Study: 14633528

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with ropivacaine 0.2%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous epidural infusion analgesia (CEA) with ropivacaine 0.2%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both PCEA and CEA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 48

Group type: COMPARATOR
Intervention: CEA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PCEA and CEA
Number of subjects: 48
Study: 11104317

Group type: EXPERIMENTAL
Intervention: Combination treatment (medication plus behavioral treatment)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Behavioral treatment alone
Number of subjects: 579

Group type: COMPARATOR
Intervention: Regular community care
Number of subjects: 579
Study: 9116551

Group type: EXPERIMENTAL
Intervention: Prescription for antibiotics for 10 days (group 1, 246 patients)
Number of subjects: 716

Group type: COMPARATOR
Intervention: No prescription (group 2, 230 patients)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Prescription for antibiotics if symptoms were not starting to settle after three days (group 3, 238 patients)
Number of subjects: 716
Study: 8443450

Group type: EXPERIMENTAL
Intervention: Modified self-tonometer with acoustic control signal and modified fixation lamp
Number of subjects: 30

Group type: COMPARATOR
Intervention: Existing self-tonometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Draeger hand-held applanation tonometer
Number of subjects: 30
Study: 3528969

Group type: EXPERIMENTAL
Intervention: FAC regimen
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: FEC regimen
Number of subjects: 239
Study: 30463611

Group type: EXPERIMENTAL
Intervention: cALND (complementary axillary lymph node dissection)
Number of subjects: 963

Group type: COMPARATOR
Intervention: SLNB (sentinel lymph node biopsy) alone
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: cALND (with chemotherapy)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: cALND (before chemotherapy)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: cALND (without chemotherapy)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Whole breast or chest wall irradiation
Number of subjects: 963
Study: 27406786

Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (100 units total; 20 units into parotid and 30 units into submandibular glands)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (various studies included in meta-analysis)
Number of subjects: 10
Study: 24837977

Group type: EXPERIMENTAL
Intervention: Ambulatory adaptation (AA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hospital adaptation (HA)
Number of subjects: 53
Study: 22767164

Group type: EXPERIMENTAL
Intervention: Optimized prolate ablation (OPA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 37
Study: 18755817

Group type: EXPERIMENTAL
Intervention: Talnetant 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haloperidol 3 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18487215

Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline (800 mg/day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 98
Study: 16864839

Group type: EXPERIMENTAL
Intervention: Myotonic dystrophy type 1 (DM1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Myotonic dystrophy type 2 (DM2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 12482765

Group type: EXPERIMENTAL
Intervention: Isoproterenol (20 and 40 ng.kg(‐1).min(‐1) for 15 min/dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propranolol (100 mg/day for 5 days)
Number of subjects: 36
Study: 10683349

Group type: EXPERIMENTAL
Intervention: Mibefradil (initial 50 mg daily dose uptitrated to 100 mg after 1 month, continued up to 3 years)
Number of subjects: 2590

Group type: COMPARATOR
Intervention: Placebo (as adjunct to usual therapy)
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Mibefradil with antiarrhythmics (class I or III, including amiodarone)
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Mibefradil and placebo (substudies)
Number of subjects: 2590
Study: 9332510

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prior antifungal therapy failed
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluconazole (400-800 mg)
Number of subjects: 39
Study: 11067180

Group type: EXPERIMENTAL
Intervention: Education intervention program in schools, with parents and community-at-large for 3 years.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed Program condition (control group).
Number of subjects: 20
Study: 2944386

Group type: EXPERIMENTAL
Intervention: Acetaminophen, 1300 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Meclofenamate, 100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Meclofenamate, 200 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 31420895

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 150
Study: 31421686

Group type: EXPERIMENTAL
Intervention: Viscosupplementation (VS) treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Responder patients
Number of subjects: 166
Study: 27923279

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control (diet only)
Number of subjects: 304
Study: 26201224

Group type: EXPERIMENTAL
Intervention: Full mouth SRP + Roxithromycin (RXM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: SRP + Placebo
Number of subjects: 70
Study: 24200619

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg administered in the morning
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg administered in the evening
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg (morning or evening)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22367374

Group type: EXPERIMENTAL
Intervention: Emollient cream containing 0.25% zinc pyrithione
Number of subjects: 60

Group type: COMPARATOR
Intervention: Emollient cream alone
Number of subjects: 60
Study: 19780002

Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50 mg tramadol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rescue analgesic (1 mg.kg(‐1) im meperidine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nausea-vomiting, bleeding, postoperative hemorrhage
Number of subjects: 40
Study: 17058027

Group type: EXPERIMENTAL
Intervention: Operation plus TACE and PVC (Group C)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Operation only (Group A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Operation plus TACE (Group B)
Number of subjects: 112
Study: 15517154

Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg
Number of subjects: 9
Study: 11318005

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 1 part per million in the supine position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of INO and prone positioning
Number of subjects: 16

Group type: COMPARATOR
Intervention: INO in the supine position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prone positioning plus INO
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mechanical ventilation in the supine position
Number of subjects: 16
Study: 9205222

Group type: EXPERIMENTAL
Intervention: Camera-based method for calculating Tc-99m MAG3 clearance
Number of subjects: 49
Study: 8486508

Group type: EXPERIMENTAL
Intervention: Sodium valproate as prophylactic migraine therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study: 3468819

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29980595

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4822

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study: 27492532

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg add-on to ICS plus LABA
Number of subjects: 912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study: 24947045

Group type: EXPERIMENTAL
Intervention: 5As Team (5AsT) intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-level outcomes
Number of subjects: 0
Study: 22104390

Group type: EXPERIMENTAL
Intervention: Autologous blood injection added to standard treatment (eccentric-loading exercises) for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard treatment (eccentric-loading exercises) alone for 12 weeks
Number of subjects: 33
Study: 20815273

Group type: EXPERIMENTAL
Intervention: Shenxiong Bushen Capsule (5 tablets, thrice a day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Piracetam (5 tablets, twice a day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Shenxiong Bushen Capsule
Number of subjects: 70

Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 18560214

Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 603
Study: 15804320

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
Number of subjects: 0
Study: 12445035

Group type: EXPERIMENTAL
Intervention: Omeprazole, 120 mg day‐1 for 7 days
Number of subjects: 12
Study: 10602832

Group type: EXPERIMENTAL
Intervention: Back school programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Back school programs at work sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Back schools with intensive training
Number of subjects: 0